Back

Effects of empagliflozin on overall heart failure burden in EMPA-REG OUTCOME

28 August 2016 (17:23 - 17:30)
Organised by:
Congress Presentation Part of: Clinical Trial Update Heart failure and Pacing Pharmacologic therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

6 More presentations in this session

Presentation thumbnail
Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS treated with cardiac resynchronization therapy: analysis of the EchoCRT trial
Professor J. Bax (Leiden, NL)
Slides Video
Presentation thumbnail
Long-term Performance of a Transcatheter Pacing System: 12 Month Results From the Micra Global Clinical Trial
Doctor P. Ritter (Bordeaux, FR)
Slides Video
Presentation thumbnail
Association between risk reduction in cardiovascular deaths or hospitalizations and CRT optimization using the SonR contractility sensor in subgroups of patients: RESPOND-CRT Trial update
Professor J. Brugada Terradellas (Barcelona, ES)
Slides Video
Presentation thumbnail
Effects of Empagliflozin on Cardiovascular Mortality by Prevalent or Incident Heart Failure in EMPA-REG OUTCOME
Doctor D. Fitchett (Toronto, CA)
Slides
Presentation thumbnail
Echocardiographic Progression and Effects of Etiologic Treatment in Chagas Cardiomyopathy: A BENEFIT Trial Echocardiographic Sub-Study
Associate Professor A. Schmidt (Ribeirao Preto, BR)
Slides Video

Access the full session

Session thumbnail
Clinical Trial Update Heart failure and Pacing

The Event

Event poster

ESC Congress 2016

28 August 2016 17:23 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources